CVAC实时信号 | 通过Getagraph.com最大化利润

购买 107680 min ago

@ $3.41

发出时间: 15 Feb 2024 @ 04:58

回报率: -27.17%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -2.14 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:36):

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
今日成交量	310 895
平均成交量	796 498
市值	555.23M
EPS	$-0.240 ( 2023-11-14 )
下一个收益日期	( $-0.140 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.580
ATR14	$0.0130 (0.52%)

音量相关性

長: -0.09 (neutral)

短: -0.98 (very strong negative)

Signal:(55.454) Neutral

CureVac AG 相关性

10 最正相关
BELFA	0.934
CVLT	0.929
BELFB	0.926
SPNS	0.922
EWZS	0.911
XP	0.91
PTC	0.91
GLDD	0.907
XOG	0.904
CSGP	0.903

10 最负相关
PAYS	-0.885
OBNK	-0.883
DTEA	-0.882
CIDM	-0.869
TRMD	-0.866
PLXP	-0.862
AY	-0.847
NLSP	-0.847
EDRY	-0.845
JRSH	-0.844

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CureVac AG 相关性 - 货币/商品

-0.15
( neutral )

-0.06
( neutral )

0.00
( neutral )

-0.01
( neutral )

-0.60
( weak negative )

-0.71
( moderate negative )

CureVac AG 财务报表

Annual	2023
营收:	$52.70M
毛利润:	$-268.58M (-509.67 %)
EPS:	$0

FY	2023
营收:	$52.70M
毛利润:	$-268.58M (-509.67 %)
EPS:	$0

FY	2022
营收:	$67.42M
毛利润:	$-116.57M (-172.91 %)
EPS:	$-1.320

FY	2021
营收:	$102.99M
毛利润:	$-135.21M (-131.28 %)
EPS:	$-2.28

Financial Reports:

No articles found.

CureVac AG

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.